Combination Immunotherapies for Non-Small Cell Lung Cancer
(ARC-7 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This randomized phase 2 open-label study will evaluate the safety and efficacy of zimberelimab (AB122) monotherapy, domvanalimab (AB154) in combination with zimberelimab, and domvanalimab in combination with zimberelimab and etrumadenant (AB928) in front-line, PD-L1 positive, metastatic non-small cell lung cancer.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot use high doses of corticosteroids or immunosuppressive drugs. It's best to discuss your specific medications with the trial team.
What safety data exists for combination immunotherapies like Domvanalimab, Etrumadenant, and Zimberelimab in humans?
The research articles reviewed do not provide specific safety data for Domvanalimab, Etrumadenant, or Zimberelimab. However, they discuss the safety of other immune checkpoint inhibitors, which generally have a favorable toxicity profile, meaning they are usually safe for human use, though they can cause immune-related adverse events (side effects related to the immune system).12345
What makes the combination of Domvanalimab, Etrumadenant, and Zimberelimab unique for treating non-small cell lung cancer?
What data supports the effectiveness of the drug combination Domvanalimab, AB 154, GS-0154, Domvanalimab, Etrumadenant, AB928, Zimberelimab, AB122 for non-small cell lung cancer?
Research shows that combining different immunotherapy drugs can improve outcomes for non-small cell lung cancer. For example, studies have found that combining drugs like pembrolizumab and ipilimumab, or using a three-drug regimen with tremelimumab and durvalumab, can extend survival and improve responses compared to chemotherapy alone.5671011
Who Is on the Research Team?
Medical Director
Principal Investigator
Arcus Biosciences, Inc.
Are You a Good Fit for This Trial?
This trial is for adults over 18 with untreated, advanced non-small cell lung cancer showing high PD-L1 expression and no EGFR or ALK tumor mutations. Participants must be relatively healthy (ECOG score of 0 or 1) and have at least one measurable lesion. They shouldn't have had other active cancers in the last two years, recent vaccines, surgeries, certain viral infections like Hepatitis B/C or HIV, gastrointestinal issues affecting oral medication intake, or require high doses of steroids.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive zimberelimab monotherapy, domvanalimab in combination with zimberelimab, or domvanalimab in combination with zimberelimab and etrumadenant
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Domvanalimab
- Etrumadenant
- Zimberelimab
Find a Clinic Near You
Who Is Running the Clinical Trial?
Arcus Biosciences, Inc.
Lead Sponsor
Gilead Sciences
Industry Sponsor
Daniel O'Day
Gilead Sciences
Chief Executive Officer since 2019
MBA from Columbia University
Dietmar Berger
Gilead Sciences
Chief Medical Officer
MD and PhD from Albert-Ludwigs University School of Medicine